← Shanghai ZJ Bio-Tech Co. Ltd. A overview

Shanghai ZJ Bio-Tech Co. Ltd. A vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai ZJ Bio-Tech Co. Ltd. A (688317.CG)

Q3 2026
▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

  • New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.

    These approvals are the main positive catalysts that could drive future sales and investor optimism.

  • Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.

    The widening loss is the key fundamental negative that pressures the share price.

  • Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.

    Buybacks are a capital action that can cushion the stock and show insider confidence.

August 2026
▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

  • New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.

    These approvals are the main positive catalysts that could drive future sales and investor optimism.

  • Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.

    The widening loss is the key fundamental negative that pressures the share price.

  • Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.

    Buybacks are a capital action that can cushion the stock and show insider confidence.

Latest
▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

  • New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.

    These approvals are the main positive catalysts that could drive future sales and investor optimism.

  • Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.

    The widening loss is the key fundamental negative that pressures the share price.

  • Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.

    Buybacks are a capital action that can cushion the stock and show insider confidence.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.